Shares of Novo Nordisk ended higher on Monday and extended gains in after-hours trading, while "Big Pharma" rival Eli Lilly ...

The decision counters a proposal by the Biden Administration to reimburse beneficiaries for the weight-loss medications.

Novo Nordisk joined the many pharmaceutical companies pushing back on government-negotiated drug pricing in the United States.

The decision is a setback for GLP-1 drugmakers, though it's not entirely surprising given the Trump administration’s focus on ...

The Trump administration reversed a Biden-era proposal for Medicare coverage of anti-obesity treatments. But on Monday, HHS ...

We had not assumed this proposed rule would pass, and we continue to think Novo and Lilly will gain Medicare obesity drug coverage via overlapping indications with time, such as Zepbound’s ...

Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.

Last week, the Centers for Medicare & Medicaid Services said it will not go ahead with a plan from the Biden administration ...

A proposal by the Biden administration to cover weight-loss medicines for obesity under Medicare has been axed by the White ...

The proposal would have enabled more Americans to afford new medications in the GLP-1 class that have been shown to reduce ...

The U.S. announced an increase in Medicare Advantage payment rates for 2026, exceeding expectations and affecting insurer ...